Cost-effectiveness of vortioxetine versus escitalopram and venlafaxine XR as first-line treatments of severe major depressive disorder in Finland.
The aim of this study is to assess the cost-effectiveness of the most recently approved treatment (vortioxetine) with current standards of pharmacological care for MDD in Finland (escitalopram, venlafaxine). This knowledge is expected to contribute towards current HTA literature in Finland and assess the cost-effectiveness of current care practices. As cost-effectiveness studies in the Finnish context are less than extensive and none exist specifically considering first-line treatment, this study aims to address a relevant research question: “How cost-effective is vortioxetine as compared to escitalopram and venlafaxine XR in first-line treatment of major depressive disorder in Finland?”
Prosjektbeskrivelse med vedlegg
Disse dokumentene er kun synlige for prosjektleder, enhetens leder og forskningsadministrasjon.
- Begrunnelse: Bruke data innhentet fra litereaturen
Prosjektet har ingen godkjenninger